Search

everythinglearnresearchcommunity

for

Search:↓

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

PRP injections improve skin appearance and are safe for treating morphea.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

PRP is a promising alternative for alopecia areata due to its safety and patient satisfaction.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Platelet-rich concentrates can be an alternative treatment for oral lichen planus, especially when steroids don't work.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.

Platelets and their derivatives, like PRP, can help tissue regeneration, but need standardized safety protocols.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Platelet-rich plasma may help heal injuries.

Rituximab effectively managed a difficult case of juvenile lupus with complications, reducing the need for steroids.

Ritlecitinib is safe and may effectively treat alopecia areata.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

PRF lysates reduce inflammation in cancer cells and boost immune response in healthy oral cells.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

PLD is an effective and safer alternative for treating breast cancer.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Autologous Platelet and Extracellular Vesicle-Rich Plasma (PVRP) has potential in enhancing tissue regeneration and improving hair conditions, but its effectiveness varies due to individual differences.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.